-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A few days ago, Xencor and Bristol Myers Squibb (Bristol Myers Squibb) signed a license agreement for the use of Xtend XmAb technology.
Bristol Myers Squibb will use Xencor's technology to extend the half-life of SARS-CoV-2 neutralizing monoclonal antibody combination therapy
.
Bristol-Myers Squibb’s progress in the treatment of COVID-19 has been relatively slow.
Xencor is a clinical-stage biopharmaceutical company dedicated to the development of engineered monoclonal antibodies and antibodies for the treatment of cancer and autoimmune diseases.
Cytokines
.
After the agreement is signed, Bristol-Myers Squibb will have the non-exclusive right to use Xencor's Xtend Fc technology.
SARS-CoV-2 mAb Duo was originally discovered by researchers at Rockefeller University.
In February of this year, Bristol-Myers Squibb obtained a license to use the therapy
.
Currently, researchers at Rockefeller University Hospital are conducting a phase 1 clinical trial of this therapy to evaluate the appropriate dosage and safety of the antibody combination
Bristol-Myers Squibb plans to quickly enter the registration study after the completion of the first phase
.
As part of the NIH ACTIV-2 trial, Phase 2 and Phase 3 trials will study the treatment of this therapy for outpatients with COVID-19 infection
According to the terms of the agreement, Bristol-Myers Squibb will be solely responsible for supporting and advancing the research, development, regulatory application and commercial activities of SARS-CoV-2 mAb Duo
.
If the therapy can be produced and sold in the future, Xencor is eligible to collect royalties from the net sales profits of products that include these antibodies
The progress of the Bristol-Myers Squibb antibody portfolio is far behind that of companies such as Eli Lilly and Regeneron, which have similar treatment methods.
At present, the anti-SARS-CoV-2 antibodies of these two companies have obtained emergency authorization from the FDA
.
Eli Lilly’s bamlanivimab brought in $871 million in revenue in the fourth quarter of 2020
The FDA also revoked the emergency use authorization of bamlanivimab monotherapy
.
Eli Lilly's combination therapy and regenerative casirivimab and imdevimab combination therapy are authorized to treat mild to moderate COVID-19 infections
Reference source:
1.
2.
